ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Arno Therapeutics Inc (CE)

Arno Therapeutics Inc (CE) (ARNI)

0,0001
0,00
(0,00%)
Fermé 14 Janvier 10:00PM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
0,0001
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,000058 Plage de 52 semaines 0,0003
Clôture Veille
0,0001
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
14 983
Volume financier
-
VWAP
-

ARNI Dernières nouvelles

Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief...

FLEMINGTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

FLEMINGTON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Reports First Quarter 2014 Financial and Business Update

FLEMINGTON, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men's and Women's Cancers at 2014 ASCO Annual Meet...

Studies to determine recommended Phase II dose and safety profile of lead compound Will analyze relationship of biomarker to any anti-tumor activity observed FLEMINGTON, N.J., May 14, 2014...

Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting

FLEMINGTON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistan...

FLEMINGTON, N.J., April 7, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones

FLEMINGTON, N.J., April 1, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014...

FLEMINGTON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman

FLEMINGTON, N.J., March 24, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Present at 26th Annual ROTH Conference

FLEMINGTON, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
12000.00010.00010.0001149830.0001CS
26-0.0002-66.66666666670.00030.00030.000174920.0001CS
524.2E-572.41379310345.8E-50.00035.8E-537570.00012027CS
156-0.002-95.23809523810.00210.00211.0E-665097.433E-5CS
260-0.0017-94.44444444440.00180.0421.0E-6651420.00491568CS

ARNI - Frequently Asked Questions (FAQ)

What is the current Arno Therapeutics (CE) share price?
The current share price of Arno Therapeutics (CE) is US$ 0,0001
What is the 1 year trading range for Arno Therapeutics (CE) share price?
Arno Therapeutics (CE) has traded in the range of US$ 0,000058 to US$ 0,0003 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
VICPVicapsys Life Sciences Inc (CE)
US$ 1,50
(149 999 900,00%)
207
CRSQCorporate Restaurant Concepts Inc (PK)
US$ 0,99
(82 400,00%)
500
PSRUValiant Eagle Inc (PK)
US$ 0,0002
(19 900,00%)
42,27M
CCTLCoin Citadel (PK)
US$ 0,0002
(19 900,00%)
100k
MOPNMOP Environmental Solutions Inc (CE)
US$ 0,0001
(9 900,00%)
32k
INOQTPT Strategic Inc (CE)
US$ 0,000001
(-100,00%)
500
VGTLVGTel Inc (CE)
US$ 0,000001
(-99,50%)
200k
IFANIFAN Financial Inc (CE)
US$ 0,000001
(-99,50%)
1 000
VAXXVaxxinity Inc (CE)
US$ 0,0004
(-99,20%)
15,6k
GLCOGlobal Links Corporation New (CE)
US$ 0,000001
(-99,00%)
1,5k
PHILPHI Group Inc (PK)
US$ 0,0003
(20,00%)
350,65M
ABQQAB International Group Corporation (PK)
US$ 0,0007
(0,00%)
227,81M
HMBLHUMBL Inc (PK)
US$ 0,0009
(0,00%)
200,68M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0,0037
(-1,33%)
141,32M
RDARRaadr Inc (PK)
US$ 0,0012
(4,35%)
138,46M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées